Technology
Health
Pharmaceutical

BiondVax Pharmaceuticals

$6.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (1.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BVXV and other stocks, options, ETFs, and crypto commission-free!

About

BiondVax Pharmaceuticals Ltd. American Depositary Shares, also called BiondVax Pharmaceuticals, is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. Read More It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.

Employees
21
Headquarters
Jerusalem, Jerusalem
Founded
2003
Market Cap
43.13M
Price-Earnings Ratio
Dividend Yield
Average Volume
5.90K
High Today
$6.69
Low Today
$6.54
Open Price
$6.55
Volume
1.80K
52 Week High
$7.26
52 Week Low
$3.51

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2015 IPO
Asia (Non-China)
Asia

News

Yahoo FinanceMay 13

BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference

JERUSALEM, Israel, May 13, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel. BiondVax Pharmaceuticals Logo (PRNewsfoto/Biondvax Pharmaceuticals Ltd) More Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical effic...

34
Yahoo FinanceApr 30

BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update

JERUSALEM, April 30, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate currently undergoing a pivotal clinical efficacy Phase 3 trial, today announced its fourth quarter and full year financial results for the year ended December 31, 2018 and provided a business update. BiondVax Pharmaceuticals Logo (PRNewsfoto/Biondvax Pharmaceuticals Ltd) More Fourth Quarter 2018 Financial Summary Res...

20

Earnings

-$0.05
-$0.03
-$0.02
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.05 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.